Covid-19 triggers research culture in Ayurveda, traditional medicines

Of 203 trials registered with the Clinical Trial Registry, 61.5% are from Ayush disciplines

GN Bureau | September 30, 2020


#Covid-19   #Novel Coronavirus   #healthcare   #Ayush ministry   #Ayurveda   #Yoga  
(Illustration: Ashish Asthana)
(Illustration: Ashish Asthana)

The Covid-19 pandemic has brought the spotlight on the health-promotive and disease-preventive solutions of Ayush (Ayurveda, Yoga, Unani, Siddha, Homeopathy) disciplines. What has not come into the limelight is the emerging nationwide trend in the Ayush disciplines, of taking up evidence-based studies.

A study made a thorough search of the Clinical Trial Registry of India for the registered trials of Covid-19 involving ayurveda intervention from March 1 to June 25, without language restrictions. The number of new trials registered in Ayurveda during this period was seen to be 58, the Ayush ministry said in a release on Wednesday.

News reports in August had revealed that out of the 203 trials registered in Clinical Trial Registry of India (CTRI), 61.5% were from Ayush disciplines. A recent study published in the ‘Journal of Research in Ayurvedic Sciences’ titled “Ayurveda Research Studies on Covid-19 Registered in CTRI: A critical appraisal” throws more light on this growing “research-culture” in Ayush disciplines.

Here is some additional insight into these CTRI registered trials involving Ayurveda and Covid-19. Approximately 70% of the total trials registered were sponsored by the government and various stakeholders of Ayurveda associated with the Ayush ministry. These trials will provide useful information to the researchers which will help them to strategize the next course of action and also help the general public for understanding the contribution of Ayurveda in Covid-19.

Once completed, the results of these promising studies will expectedly be published at the earliest so that it will be useful for the policymakers from the Ayush systems of medicines to strategize effective solutions to benefit public health initiatives. Further, in these challenging times, they will provide information for the global scientific community to know about the outcomes of Ayurveda clinical trials being conducted on Covid-19 in India. They will form potential source of information for further collaborative studies at the national and global levels.

Out of the 58 registered trials, 52 (89.66%) are interventional trials and 6 (10.34%) are observational trials. The majority of the trials included adult participants of both the gender as the target population. A total of 53 (91.38%) trials intend to recruit participants aged 18 years or more, and only 05 (8.62%) trials intended to recruit participants younger than 18 years.

The instant paper, which is authored by researchers of the Central Council for Research in Ayurvedic Sciences, provides detailed information about Ayurveda based Covid-19 clinical trials with respect to administrative information on trial registry number and sponsorship, descriptive information on study type and length of study and study design. Further, it tracks information related to the registration date and actual study start date and information related to recruitment, and all these have been collated, presented, and analysed based on the trails’ information registered between March 1 and June 25 in the CTRI.

With an increasing number of registered trials in this field, the body of knowledge in Ayush disciplines will increasingly reflect more contemporary information. This trend of evidence-based studies in the Ayush sector holds considerable promise for the public health activities in the country, as the studies may lead to cost-effective solutions that could be deployed on a nationwide scale.

Comments

 

Other News

`Development must be judged beyond GDP, with rights and justice at core`

Delivering the IXth Chief Justice M.C. Chagla Memorial Lecture on ‘Human Rights and Sustainable Development Goals’, in Mumbai Friday,  former Chief Justice of India Bhushan R. Gavai questioned whether conventional economic indicators such as gross domestic product (GDP), national income,

RTI exposes Rs 16,909 crore cost blowout on Mumbai-Goa Highway

Seventeen years after the centre first approved the widening of National Highway 66 between Mumbai and Goa into a four-lane highway, a fresh RTI reply has revealed a sharp escalation in the project`s sanctioned cost.   According to the RTI reply obtained by activist Jeetendra

"India`s semiconductor ecosystem is expanding rapidly"

Prime minister Narendra Modi on Thursday inaugurated SEMICON India 2026 in New Delhi. Addressing the occasion and highlighting the significance of the event`s fifth edition, the PM drew a parallel between the launch of Semicon India and Vishwakarma Diwas. He pointed out the beautiful coincidence of

Cabinet approves raising EPFO wage ceiling from Rs.15,000 p.m. to Rs.25,000

The union cabinet, chaired by the prime minister, has approved the proposal of the Ministry of Labour & Employment to enhance the wage ceiling for mandatory coverage under the Employees’ Provident Fund Organisation (EPFO) from Rs.15,000 to Rs.25,000 per month. The decision is expected to bring

UPI continues to remain free for peer-to-peer transactions: Finance Ministry

The new UPI framework introduced has no impact on any person to person transactions, and UPI will continue to remain completely free for all person-to-person transactions, irrespective of the amount transferred, the finance ministry clarified on Tuesday.   Payments to merchan

SEMICON India 2026 and the making of a chip powerhouse

On Thursday, prime minister Narendra Modi will inaugurate SEMICON India 2026 at Yashobhoomi in Dwarka, New Delhi. Global chipmakers, policymakers and investors will fill the halls, all watching an industry India has built from the ground up. For three days, the country`s semi-con (semiconductor) manufact

Upcoming Conferences



-->

Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter